RELATIONSHIP BETWEEN IN VIVO FK506 CLEARANCE AND IN VITRO 13-DEMETHYLATION ACTIVITY IN LIVING-RELATED LIVER TRANSPLANTATION
- 1 October 1998
- journal article
- research article
- Published by Wolters Kluwer Health in Transplantation
- Vol. 66 (8) , 1089-1093
- https://doi.org/10.1097/00007890-199810270-00020
Abstract
Although it is important to maintain an appropriate blood concentration of FK506 after liver transplantation, significant interindividual variability in the actual FK506 dosage has been observed, presumably due to the wide variability of cytochrome P450 3A4 activity in liver microsomes. A study was conducted in patients undergoing living-related liver transplantation and their donors to investigate the relationship between the in vitro FK506 demethylation activity in graft liver microsomes and the in vivo blood clearance of FK506. Liver biopsy tissue was obtained from 17 living donors to measure the in vitro formation rate of 13-demethyl derivative (M-I: the major metabolite of FK506). Erythromycin N-demethylation activity in vitro was also assessed in 11 cases. The FK506 blood clearance (CLss) was calculated from its constant infusion rate and steady-state blood concentration on day 4 after transplantation in 17 recipients. The FK506 infusion rate varied 4.6-fold from 8.3 to 38.4 ng/min/kg. The mean CLss of FK506 was 22.1±10.8 ml/min (10.1-45.2 ml/min). The M-I formation rate showed a wide variability, ranging from 0.098 to 0.571 nmol/min/mg protein. A significant correlation was observed between the in vitro estimated total metabolic ability of the graft for FK506 (M-I formation rate × graft weight) and the in vivo CLss of FK506 (r=0.770, P<0.001). Erythromycin N-demethylation (0.066-0.443 nmol/min/mg protein) showed a strong correlation with the M-I formation rate (r=0.891, P<0.01). The in vivo FK506 clearance can mainly reflect in vitro FK506 demethylation activity.Keywords
This publication has 18 references indexed in Scilit:
- Erythromycin Breath Test and Clinical TransplantationTherapeutic Drug Monitoring, 1996
- Clinical Pharmacokinetics of TacrolimusClinical Pharmacokinetics, 1995
- Calculation of child and adult standard liver volume for liver transplantationHepatology, 1995
- Severe neurological complications following orthotopic liver transplantation in patients receiving FK 506 and prednisoneJournal of Hepatology, 1994
- Noninvasive tests of CYP3A enzymesPharmacogenetics, 1994
- Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejectionThe Lancet, 1994
- Importance of cytochrome P-450IIIA activity in determining dosage and blood levels of FK 506 and cyclosporine in liver transplant recipientsHepatology, 1994
- RELATIONSHIP BETWEEN GRAFT CYTOCHROME P-450 3A CONTENT AND EARLY MORBIDITY AFTER LIVER TRANSPLANTATION1Transplantation, 1993
- OPTIMIZATION OF CYCLOSPORINE THERAPY IN RENAL TRANSPLANTATION BY A PHARMACOKINETIC STRATEGYTransplantation, 1988
- Simultaneous purification of multiple forms of rat liver microsomal cytochrome P-450 by high-performance liquid chromatographyBiochimica et Biophysica Acta (BBA) - General Subjects, 1985